Abiopharma

Poseida Therapeutics (PSTX) Announces Regulatory Update Poseida Therapeutics (PSTX) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: • Status: Rejected Clinical Development:

• anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry and the other risks described in Poseida’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. ### Investor contact: Alex Lobo Stern Investor Relations Alex.lobo@sternir.com Media contact: Sarah Thailing Senior Director, Corporate Communications and IR Poseida Therapeutics, Inc. 858-605-3717